ArticleFrontiers in microbiology2012
Antibody therapy for histoplasmosis.
Article in Frontiers in microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Lectin-Fc(IgG) fusion proteins exhibit antifungal activity against the emerging multidrug-resistant pathogenInfection and immunity · 2025Article
- How Histoplasma Evades the Human Immune System.Acta medica academica · 2025Review
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Design of a Multi-Epitope Vaccine againstJournal of fungi (Basel, Switzerland) · 2024Article
- Immunoproteomic and Immunopeptidomic Analyses ofFrontiers in immunology · 2021Article
- Monoclonal Antibodies as Tools to Combat Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020Review
- Immunoproteomics Reveals Pathogen's Antigens Involved inFrontiers in cellular and infection microbiology · 2020Article
- Immunization Strategies for the Control of Histoplasmosis.Current tropical medicine reports · 2019Article
- Histoplasma Capsulatum: Mechanisms for Pathogenesis.Current topics in microbiology and immunology · 2019Review
- Concentration-dependent protein loading of extracellular vesicles released by Histoplasma capsulatum after antibody treatment and its modulatory action upon macrophages.Scientific reports · 2018Article
- Characterization of the antifungal functions of a WGA-Fc (IgG2a) fusion protein binding to cell wall chitin oligomers.Scientific reports · 2017Article
- Editorial: Vaccines, Immunotherapy and New Antifungal Therapy against Fungi: Updates in the New Frontier.Frontiers in microbiology · 2017Article
- Histoplasma capsulatum, lung infection and immunity.Future microbiology · 2015Review
- Vaccines and immunotherapy against fungi: the new frontier.Frontiers in microbiology · 2013Article
- Article
- Vaccine development for pathogenic fungi: current status and future directions.Expert review of vaccinesReview
- The Einstein-Brazil Fogarty: A decade of synergy.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]Review
- Pulmonary histoplasmosis presenting with a halo sign on CT in an immunocompetent patient.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e TisilogiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endemic human pathogenic fungus Histoplasma capsulatum is a major fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10 years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.